Patients
![[title-raw]](http://www.ahmf.com.au/sites/default/files/images/%5Btype%5D/teasers/%5Btitle-raw%5D/live_and_love_film_competition_thumbnail.jpg?1282630604) |
Live and Love: A Short Film Competition about Herpes Make a 30 second film about HSV for a chance to win $30,000 in the AHMF's Live & Love short film competition. We invite film makers to create a 30 second work to destigmatise herpes (HSV). Encourage conversation, debunk myths, break the taboo... allow your viewers to be transported to a world where their minds are open to a subject they would normally dismiss. The competition is open to: |
![[title-raw]](http://www.ahmf.com.au/sites/default/files/images/%5Btype%5D/teasers/%5Btitle-raw%5D/research-presentation.jpg?1243252450) |
AHMF research to be presented internationally In 2007, the AHMF conducted an online survey to determine how many people were at risk of having herpes. The results are about to be presented to a wide international audience. |
![[title-raw]](http://www.ahmf.com.au/sites/default/files/images/%5Btype%5D/teasers/%5Btitle-raw%5D/2-day-treatment.jpg?1243252492) |
Two-day treatment course for genital herpes A new two-day course of famciclovir (available in Australia as Famvir) has been licensed for treating outbreaks of genital herpes. The new course consists of a single 500mg dose, followed by three doses of 250mg. |
|
Online survey helps determine those likely to have herpes 36 per cent of survey participants found to be at high risk of contracting the virus. |
